logo-loader
RNS
viewTissue Regenix Group PLC

Unaudited Interim Results

/**/ sup{font-size:80%}h2{margin-right:0cm;margin-left:0cm;font-size:18.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: purple } .av{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.av{}p.hp{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; margin-bottom: 0cm}span.hn{font-size:10.0pt;line-height:115%;font-family:"Arial","sans-serif"}p.hq{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: 107%; margin-bottom: 8.0pt; text-align: center}span.hl{font-size:10.0pt;line-height:107%;font-family: "Arial","sans-serif"}p.hr{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:8.0pt;line-height:107%}span.hj{font-size:10.0pt;line-height:107%;font-family:"Arial","sans-serif"}p.hs{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt}p.ht{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; margin-bottom: 0cm} p.hu{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-18.0pt}span.hf{font-size:10.0pt;line-height:115%;font-family:Symbol}p.hv{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:0cm;margin-bottom: 0cm;margin-left:54.0pt;margin-bottom:.0001pt;text-indent:-18.0pt}span.hd{font-size:10.0pt;line-height:115%}p.hw{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:0cm;margin-bottom: 0cm;margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-18.0pt}span.ha{font-size:10.0pt;line-height:115%;font-family: "Arial","sans-serif"}p.hx{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt}span.gz{font-size:8.0pt;line-height:115%;font-family:"Arial","sans-serif"}p.hy{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:72.0pt;margin-bottom:.0001pt;text-indent:-18.0pt}span.gy{font-size:10.0pt;line-height:115%;font-family:"Courier New"} span.gw{font-size:10.0pt; line-height:115%;font-family:"Arial","sans-serif"}span.gv{font-size:10.0pt;line-height:115%; font-family:"Arial","sans-serif"}p.hz{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:36.0pt;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt; text-indent:-18.0pt}span.gu{font-size:10.0pt;line-height:115%; font-family:Symbol}table.ia{border-collapse:collapse}td.gr{width:294.0pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.ib{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 107%; margin-bottom: 8.0pt}td.gq{width:159.3pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.gp{width:294.0pt;border:none;padding:0cm 5.4pt 0cm 5.4pt}td.go{width:159.3pt;border:none;padding:0cm 5.4pt 0cm 5.4pt} td.gn{width:294.0pt;border:none;border-bottom:solid #D7D7D7 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.gm{width:159.3pt;border:none;border-bottom:solid #D7D7D7 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.ic{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; line-height: 107%; margin-bottom: 8.0pt}p.id{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; margin-bottom: 0cm; text-decoration: underline}span.gi{color:black}span.gh{font-size:10.0pt;line-height:115%;font-family:"Arial","sans-serif"; color:black}p.ie{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify}div.ge{border:none;border-bottom:solid windowtext 1.0pt;padding:0cm 0cm 1.0pt 0cm}p.if{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Helvetica","sans-serif";color:black;border: none; font-weight: bold; line-height: 115%; padding: 0cm; text-align: justify}p.ig{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Helvetica","sans-serif";color:black;font-weight: bold; line-height: 115%; text-align: justify} table.ih{margin-left:auto;margin-right:auto;width:462.1pt;border-collapse:collapse}td.ga{width:207.25pt;border:none;border-bottom: solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt}p.ii{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Helvetica","sans-serif";color:black;text-align:justify;line-height:115%}span.gc{font-size:10.0pt;line-height:115%;font-family:"Arial","sans-serif"; color:windowtext}td.fz{width:24.65pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.fx{width:60.05pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.ij{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Helvetica","sans-serif";color:black;font-weight: bold; line-height: 115%; text-align: right}td.fw{width:60.1pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.fv{width:56.05pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.fu{width:207.25pt;border:none;padding:0cm 5.4pt 0cm 5.4pt} td.fs{width:24.65pt;border:none;padding:0cm 5.4pt 0cm 5.4pt}p.ik{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Helvetica","sans-serif";color:black;line-height: 115%; text-align: center}td.fr{width:60.05pt;border:none;padding:0cm 5.4pt 0cm 5.4pt}td.fq{width:60.1pt;border:none;padding:0cm 5.4pt 0cm 5.4pt}td.fp{width:56.05pt;border:none;padding:0cm 5.4pt 0cm 5.4pt}td.fo{width:207.25pt;padding:0cm 5.4pt 0cm 5.4pt}td.fn{width:24.65pt;padding:0cm 5.4pt 0cm 5.4pt}td.fl{width:60.05pt;padding:0cm 5.4pt 0cm 5.4pt}p.il{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Helvetica","sans-serif";color:black;line-height: 115%; text-align: right}td.fk{width:60.1pt;padding:0cm 5.4pt 0cm 5.4pt} td.fj{width:56.05pt;padding:0cm 5.4pt 0cm 5.4pt}td.fi{width:207.25pt;border:none;border-top:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.fh{width:24.65pt;border:none;border-top:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.fg{width:60.05pt;border:none;border-top:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.ff{width:60.1pt;border:none;border-top:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.fe{width:56.05pt;border:none;border-top:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.im{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Helvetica","sans-serif";color:black;margin-left:108.0pt;text-align:justify;line-height: 115%}br.fa{page-break-before:always}.aw{size:841.9pt 595.3pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.aw{} p.in{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; margin-bottom: 0cm; text-align: justify}table.io{margin-left:auto;margin-right:auto;border-collapse:collapse}td.ey{width:67.2pt;padding:0cm 5.4pt 0cm 5.4pt}td.ew{width:237.25pt;border:none; border-bottom:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt}p.ip{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; margin-bottom: 0cm; text-align: center}td.ev{width:237.25pt;padding:0cm 5.4pt 0cm 5.4pt}td.eu{width:67.2pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.er{width:38.8pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.iq{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; margin-bottom: 0cm; text-align: right}span.et{font-size:7.0pt;line-height:115%; font-family:"Arial","sans-serif"} td.eq{width:38.8pt;border-top:solid windowtext 1.0pt; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none; padding:0cm 5.4pt 0cm 5.4pt}td.ep{width:38.85pt;border-top:solid windowtext 1.0pt; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none; padding:0cm 5.4pt 0cm 5.4pt}td.eo{width:38.85pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}span.en{font-size:9.0pt;line-height:115%;font-family:"Arial","sans-serif"}p.ir{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom: 0cm; text-align: right}span.em{font-size:9.0pt;line-height:115%;font-family: "Arial","sans-serif"}span.ek{font-size:9.0pt;line-height:115%; font-family:"Arial","sans-serif"}span.ej{font-size:9.0pt; line-height:115%;font-family:"Arial","sans-serif"}td.ei{width:67.2pt;border:none;padding:0cm 5.4pt 0cm 5.4pt}td.eh{width:38.8pt;border:none;padding:0cm 5.4pt 0cm 5.4pt} td.eg{width:38.85pt;border:none;padding:0cm 5.4pt 0cm 5.4pt}td.ef{width:38.8pt;padding:0cm 5.4pt 0cm 5.4pt}td.ee{width:38.85pt;padding:0cm 5.4pt 0cm 5.4pt}span.ed{font-size:9.0pt;line-height: 115%;font-family:"Arial","sans-serif"}td.ec{width:67.2pt;border-top:solid windowtext 1.0pt; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none; padding:0cm 5.4pt 0cm 5.4pt}span.eb{font-size: 9.0pt;line-height:115%;font-family:"Arial","sans-serif"}span.ea{font-size:9.0pt;line-height:115%;font-family:"Arial","sans-serif"; color:black}.ax{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.ax{}table.is{width:462.1pt;margin-left:-5.4pt;border-collapse:collapse} td.dz{width:200.15pt;border:none;border-bottom: solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt}td.dy{width:31.75pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.dx{width:200.15pt;border:none;padding:0cm 5.4pt 0cm 5.4pt}td.dw{width:31.75pt;border:none;padding:0cm 5.4pt 0cm 5.4pt}td.dv{width:200.15pt;padding:0cm 5.4pt 0cm 5.4pt}td.du{width:31.75pt;padding:0cm 5.4pt 0cm 5.4pt}p.it{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Helvetica","sans-serif";color:black;line-height:115%}span.ds{font-size:10.0pt; line-height:115%;font-family:"Arial","sans-serif";color:windowtext}td.dq{width:200.15pt;border-top:solid windowtext 1.0pt; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none; padding:0cm 5.4pt 0cm 5.4pt}td.dp{width:31.75pt;border-top:solid windowtext 1.0pt; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none; padding:0cm 5.4pt 0cm 5.4pt} td.do{width:60.05pt;border-top:solid windowtext 1.0pt; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none; padding:0cm 5.4pt 0cm 5.4pt}td.dn{width:60.1pt;border-top:solid windowtext 1.0pt; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none; padding:0cm 5.4pt 0cm 5.4pt}td.dm{width:56.05pt;border-top:solid windowtext 1.0pt; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none; padding:0cm 5.4pt 0cm 5.4pt}tr.dg{height:12.1pt}td.dl{width:200.15pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:12.1pt}td.dk{width:31.75pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:12.1pt}td.dj{width:60.05pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:12.1pt}td.di{width:60.1pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:12.1pt}td.dh{width:56.05pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:12.1pt}tr.da{height:6.0pt} td.df{width:200.15pt;padding:0cm 5.4pt 0cm 5.4pt; height:6.0pt}td.de{width:31.75pt;padding:0cm 5.4pt 0cm 5.4pt; height:6.0pt}td.dd{width:60.05pt;padding:0cm 5.4pt 0cm 5.4pt; height:6.0pt}td.dc{width:60.1pt;padding:0cm 5.4pt 0cm 5.4pt; height:6.0pt}td.db{width:56.05pt;padding:0cm 5.4pt 0cm 5.4pt; height:6.0pt}td.cz{width:200.15pt;border:none;border-bottom: solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt;height:6.0pt}td.cy{width:31.75pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:6.0pt}td.cx{width:60.05pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:6.0pt}td.cw{width:60.1pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:6.0pt}td.cv{width:56.05pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:6.0pt} p.iu{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;text-autospace:none}p.iv{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Helvetica","sans-serif";color:black;font-weight: bold; line-height: 115%; margin-left: 18.0pt; text-align: justify; text-indent: -18.0pt}p.iw{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Helvetica","sans-serif";color:black;margin-left:36.0pt;text-align:justify;text-indent:-18.0pt; line-height:115%}span.cs{font-size:10.0pt;line-height:115%;font-family: Symbol}p.ix{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:36.0pt;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin:0cm;margin-bottom:.0001pt;text-align: justify}span.cp{font-size:11.0pt;line-height:115%;font-family:"Calibri","sans-serif"}p.a,li.a,div.a{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";}table.iy{width:421.0pt;margin-left:-5.4pt;border-collapse:collapse}tr.cg{height:15.0pt}td.cn{width:77.85pt;border:none;border-bottom:solid black 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:15.0pt} span.co{font-size:10.0pt;line-height:115%; font-family:"Arial","sans-serif";color:black}td.cm{width:49.4pt;padding:0cm 5.4pt 0cm 5.4pt; height:15.0pt}td.cl{width:71.0pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.0pt}td.ck{width:39.05pt;padding:0cm 5.4pt 0cm 5.4pt; height:15.0pt}td.cj{width:38.95pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.0pt}td.ci{width:30.15pt;padding:0cm 5.4pt 0cm 5.4pt; height:15.0pt}td.ch{width:39.0pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.0pt}tr.bx{height:15.75pt}td.cf{width:49.4pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt}td.cd{width:71.0pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt} span.ce{font-size:10.0pt;line-height:115%;font-family: "Arial","sans-serif";color:black}td.cc{width:39.05pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt}td.cb{width:38.95pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt}td.bz{width:30.15pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt}p.iz{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom: 0cm; text-align: center}td.by{width:39.0pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt}td.bw{width:77.85pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.0pt}td.bv{width:77.85pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt}td.bt{width:78.2pt;border:none;border-bottom:solid black 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:15.0pt}td.bs{width:39.2pt;padding:0cm 5.4pt 0cm 5.4pt; height:15.0pt} td.br{width:80.2pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.0pt}td.bq{width:39.2pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.0pt}td.bp{width:30.2pt;padding:0cm 5.4pt 0cm 5.4pt; height:15.0pt}td.bo{width:39.2pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt}td.bn{width:80.2pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt}td.bm{width:39.2pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt}td.bl{width:30.2pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt}td.bk{width:78.2pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.0pt}td.bj{width:78.2pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:15.75pt}table.ja{width:16.0cm;margin-left:-5.4pt;border-collapse:collapse} td.bi{width:194.05pt;border:none;border-bottom: solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt}td.bh{width:25.35pt;border:none;border-bottom:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.bg{width:194.05pt;border:none;padding:0cm 5.4pt 0cm 5.4pt}td.bf{width:25.35pt;border:none;padding:0cm 5.4pt 0cm 5.4pt}td.be{width:194.05pt;padding:0cm 5.4pt 0cm 5.4pt}td.bd{width:25.35pt;padding:0cm 5.4pt 0cm 5.4pt}td.bc{width:194.05pt;border:none;border-top:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.bb{width:25.35pt;border:none;border-top:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}table.jb{width:462.15pt;margin-left:-5.4pt;border-collapse:collapse}p.jc{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Helvetica","sans-serif";color:black;font-weight: bold; line-height: 115%; text-align: center} /**/
RNS Number : 7179L
Tissue Regenix Group PLC
10 September 2019
 

 

 

Tissue Regenix Group plc

 

Unaudited Interim Results for the six months ended 30 June 2019  

 

Leeds, 10 September 2019 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or the "Group") the regenerative medical devices company announces its unaudited interim results for the six months ended 30 June 2019.

 

Highlights

 

Financial 

·      Group sales increased to £6.1m (H1 2018: £5.6m)

-       DermaPure increased sales by 33% to £2.0m (H1 2018: £1.5m)

-       GBM-v revenue growth of 19% to £1.1m (H1 2018: £0.9m)

-       Orthopaedics & Dental sales were affected by a realigning of manufacturing to address capacity in H2 but still delivered sales of £3.0m (H1 2018: £3.2m)

·      Group EBITDA* loss of £3.6m (H1 2018: £3.5m)

·      Cash balance of £10.1m (H1 2018: £12.2m), post-$7.5m drawdown under a credit facility secured for up to $20m to invest in meeting growing demand for products

 

*EBITDA is a non-IFRS measure that the Group uses to assess its performance. It is defined as earnings before interest, taxation, depreciation and amortisation

 

Commercial  

·      Accelerating US market penetration

Expanded Group Purchasing Organisation coverage for DermaPure®

Commissioned SurgiPure® XD post marketing clinical data collection trial

·      Continue to exploit global market potential 

Entered Latin America for the first time through a distribution agreement for BioRinse® products in Chile

·      Working towards strengthened portfolio

Submitted positive two-year clinical data for OrthoPure XT to the notified body

 

Operational

·      Commenced second shift for BioRinse® products

·      Appointed US President of Operations

·      Supply chain improvement to deliver efficiencies

 

Post period

·      John Samuel resumed position of Executive Chairman, Gareth Jones appointed Interim Chief Executive Officer and Mike Barker appointed Chief Financial Officer following the resignation of Steve Couldwell as Chief Executive Officer due to a recurrence of his illness.

 

 

Executive Chairman, John Samuel, commented: "We have strong global demand for our products, which allowed us to deliver continued revenue growth, demonstrated by DermaPure, which increased sales by 33% in the first half. We remain focused on short and medium term initiatives to increase capacity and alleviate supply constraints."

 

"During the first half of the year, we streamlined our supply chain activities and enhanced our operational procedures. These initiatives have enabled us to increase production capabilities within the San Antonio facility, the benefits of which will come to fruition in the second half of the year. Longer term, having secured a credit facility of up to $20m with MidCap Financial LLP, this will support our ambitious growth plans, by adding further processing capacity to the San Antonio facility and expanding our commercial footprint." 

 

"We anticipated that the year would be significantly weighted towards the second half, as announced on the 4 June 2019, at the time of the Company's results for the year ended 31 December 2018.

We continue to expect that this will be the case, and, against a background where we see the ever growing demand for our products as the business looks to increase its manufacturing capabilities, the ability to bring this on stream during the second half of the year will be key in determining the year end outcome."

 

 

For more Information:

 

Tissue Regenix Group plc

Caitlin Pearson                                 Head of Communications  

Tel: 0330 430 3073 / 07920272 441

 

 

Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)

Jonathan Senior / Alex Price / Ben Maddison

Tel:  0207 710 7600

 

 

 

FTI Consulting 

Brett Pollard / Victoria Foster Mitchell / Mary Whittow

Tel: 0203 727 1000

 

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

 

 

 

Business Review

 

BioSurgery  

The BioSurgery division (DermaPure®,) grew revenue 33% year-on-year to £2.0m, as the repositioning in the hospital space continues to gain traction. 

 

We received a further Group Purchasing Organisation (GPO) approval in April, and now have access to circa 95% of all hospitals covered under GPOs in the US. With the increasing use of the product in uro-gyneacology procedures, where we have a specialist distribution partner, ARMS Medical, and the commencement of use in maxilliofacial and dental applications, we expect continued strong demand for the BioSurgery products in the second half of the year. To satisfy growing demand we have reinstated the processing agreement with Community Tissue Services for the production of DermaPure® in order to increase capacity and have received the first products under this agreement.

 

The business continues to make good inroads into premium medical institutions within the US market and this, coupled with additional product line extensions, is anticipated to create opportunities in the near future.

 

Orthopaedics and Dental 

As we realigned manufacturing capacity for further growth in the second half of the year there was a slight dip in revenue performance during the first half of the year for the Orthopaedics and Dental division, primarily comprising of the BioRinse® portfolio.

 

We introduced a second shift during the first quarter, which has increased processing capacity, and, in conjunction with supply chain improvements, we expect to see these changes drive revenue performance in the second half of the year. The relationship with our BioRinse® strategic distribution partner, Arthrex, Inc. continues to develop as we look to explore additional market opportunities.

 

Positive two-year clinical data for OrthoPure™ XT (porcine tendon) has been submitted to the notified body and we remain optimistic that we will be awarded the CE mark during 2019

 

GBM-V

Our controlled joint venture GBM-V is now largely self-sustainable and during the period increased revenue by 19% though the sale of corneal implants, whilst it also manages the regulatory process for the CardioPure products in Germany, which remains on track for a launch during 2020.  

 

Operations and Management

Daniel Lee, appointed as President of US Operations in January 2019, has initially focused on developing the manufacturing capabilities and re-alignment of our supply chain processes at the San Antonio facility, with the introduction of a second shift, and in March 2019 the hiring of a Head of Donor Services.

 

On the orthopaedic / dental side of the business (BioRinse®), the lead-time for final products to become available is 3 months. This means that manufacturing in Q3 will be increased, following these initiatives, and this will be key in determining our final revenues for 2019.

 

 

 

 

Post balance sheet events 

As announced on 15 August 2019, we have entered into an agreement for a 10-year lease, with an option to purchase, on a 21,000sq ft manufacturing facility, adjacent to our current building in San Antonio which allows for the first phase of the expansion project to begin. Initially, the office space and warehousing will be transferred into the new facility allowing for further clean rooms to be installed in the original building. Over time, this will allow for further clean rooms to be brought on stream as required.

 

Steve Couldwell, Chief Executive Officer (CEO), informed the Board of a recurrence of his illness, and resigned his position with immediate effect in order to concentrate on his recovery. John Samuel resumed the position of Executive Chairman, Gareth Jones, Chief Operating Officer, has taken up the position of interim-CEO. Mike Barker, who has supported the Group since January was appointed as Chief Finance Officer and Director on the Board. 

 

 

Financial Overview 

 

During the first half of 2019, we have achieved a number of milestones in order to help secure our future success.  Pivotal to this was the credit agreement with MidCap Financial LLP, which has allowed us access of up to $20m of debt financing, meaning we can begin to implement our ambitious growth plans.

 

Revenue

Revenue has increased to £6.1m (H1 2018: £5.6m). BioSurgery has increased by 33% and our joint venture, GBM-V, has increased by 19% on a reported basis.  As a result of manufacturing capacity constraints in the first half, Orthopaedics and Dental revenues decreased by 5%.

 

Margin

Margin decreased in H1 from 56% to 47% reflecting short term higher cost absorption as the second shift was brought up to full efficiency and an adverse sales mix as lower BioRinse® product volumes (generally our higher margin products) contributed less to the overall total.

 

Loss for the year

Operating loss in the six months ended 30 June 2019 improved to £4,220K (H1 2018: £4,736K).

 

R&D tax credits of £352K (H1 2018: £353K) represent the estimated tax credit receivable, together with a premium of 40%, on development costs.

 

Exceptional costs of £40k represent the costs of the MidCap Financial Trust (MidCap) loan facility.

 

Cash position

Cash position for the Group at 30 June 2019 is £10.1m (H1 2018: £12.2m). The Group received the first tranche of the MidCap loan at $7.5m in June 2019, and has available the initial revolving credit facility of up to $3.0m.

 

 

Current trading and Outlook 

 

During the first half of the year, we made significant operational progress, both in terms of our production and supply chain capabilities, investment in key appointments, and secured further funding to underpin the development of the business and to allow for our continued expansion. With this now in place, the long-term outlook for our product portfolio remains positive and our focus will be on executing against our strategic focus areas to drive forward commercial momentum.

 

We continue to look at ways to develop relationships with our strategic partners and have entered investigational discussions for geographic expansion through licensing or distribution agreements with a number of additional potential partners.

 

Demand for our products is strong, evidenced by our healthy order book from key customers, which we expect to fulfil as the operational improvements come to fruition. As capacity is increased, it will allow us greater flexibility to pursue the varied commercial opportunities we see for the products in the market.

 

We anticipated that the year would be significantly weighted towards the second half, as announced on the 4 June 2019, at the time of the Company's results for the year ended 31 December 2018.

We continue to expect that this will be the case, and, against a background where we see the ever growing demand for our products as the business looks to increase its manufacturing capabilities, the ability to bring this on stream during the second half of the year will be key in determining the year end outcome.

 

 

 

 

 

 

 

 

 

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (UNAUDITED)

FOR THE SIX MONTHS TO 30 JUNE 2019

 

 

 

 

 

Notes

6 months

30 Jun 2019

(Unaudited)

£'000

6 months

30 Jun 2018

(Unaudited)

£'000

Year

31 Dec 2018

Audited

£'000

Revenue

 

6,069

5,574

11,619

Cost of sales

 

(3,225)

(2,451)

(5,702)

Gross Profit

 

2,844

3,123

5,917

Administrative expenses before exceptional items

 

(7,024)

(7,359)

(14,183)

Exceptional items

 

(40)

(500)

(423)

Total administrative expenses

 

(7,064)

(7,859)

(14,606)

Operating loss

 

(4,220)

(4,736)

(8,689)

Finance income

 

11

42

72

Finance charges

 

(183)

(146)

(262)

Loss before tax

 

(4,392)

(4,840)

(8,879)

Taxation

4

311

305

620

Loss after tax

 

(4,081)

(4,535)

(8,259)

 

 

 

 

 

Attributable to:

 

 

 

 

Equity holders of the parent

 

(4,055)

(4,446)

(8,186)

Non-controlling

 

(26)

(89)

(73)

 

 

(4,081)

(4,535)

(8,259)

 

 

 

 

 

Other comprehensive income/(expense):

 

 

 

 

Foreign currency translation differences - foreign operations

 

 

122

 

531

 

1,360

TOTAL COMPREHENSIVE EXPENSE FOR THE YEAR

 

(3,959)

(4,004)

(6,899)

 

 

 

 

 

Attributable to:

 

 

 

 

Equity holders of the parent

 

(3,933)

(3,915)

(6,826)

Non-controlling interests

 

(26)

(89)

(73)

 

 

(3,959)

(4,004)

(6,899)

 

 

 

 

 

Loss per share

 

 

 

 

Basic and diluted on loss attributable to equity holders of the parent

 

5

 

(0.35p)

 

(0.38)p

 

(0.70)p

 

    The loss for the period arises from the Group's continuing operations.

 

 

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)

FOR THE SIX MONTHS TO 30 JUNE 2019

 

 

 

Attributable to equity holders of parent

 

 

 

 

Share Capital

£000

 

 

Share Premium

£000

 

 

Merger Reserve

£000

 

Reverse Acquisition Reserve

£000

Reserve For Own Shares

£000

Share Based Payment Reserve

£000

 

Retained Earnings Deficit

£000

 

 

 

Total

£000

 

Non-controlling Interests

£000

 

Total

Equity

£000

At 31 December 2017

5,855

86,398

10,884

(7,148)

(831)

1,186

(56,413)

39,931

(409)

39,522

Loss for the period

-

-

-

-

-

-

(4,446)

(4,446)

(89)

(4,535)

Other comprehensive expense

 

 

-

 

 

-

 

 

-

 

 

-

 

 

-

 

 

-

 

 

531

 

 

531

 

 

-

 

 

531

Loss and total comprehensive expense for the period

-

-

-

-

-

-

(3,915)

(3,915)

(89)

(4,004)

Exercise of share options

4

-

-

-

-

-

-

4

-

4

Share based payment expense

-

-

-

-

-

212

-

212

-

212

At 30 June 2018

5,859

86,398

10,884

(7,148)

(831)

1,398

(60,328)

36,232

(498)

35,734

Loss for the period

-

-

-

-

-

-

(3,740)

(3,740)

16

(3,724)

Other comprehensive expense

 

 

-

 

 

-

 

 

-

 

 

-

 

 

-

 

 

-

 

 

829

 

 

829

 

 

-

 

 

829

Loss and total comprehensive expense for the period

-

-

-

-

-

-

(2,911)

(2,911)

16

(2,895)

Share based payment expense

-

-

-

-

-

(269)

-

(269)

-

(269)

At 31 December 2018

5,859

86,398

10,884

(7,148)

(831)

1,129

(63,239)

33,052

(482)

32,570

Loss for the period

-

-

-

-

-

-

(4,055)

(4,055)

(26)

(4,081)

Other comprehensive expense

 

 

-

 

 

-

 

 

-

 

 

-

 

 

-

 

 

-

 

 

122

 

 

122

 

 

-

 

 

122

Loss and total comprehensive expense for the period

-

-

-

-

-

-

(3,933)

(3,933)

(26)

(3,959)

Share based payment expense

-

-

-

-

-

18

-

18

-

18

At 30 June 2019

5,859

86,398

10,884

(7,148)

(831)

1,147

(67,172)

29,137

(508)

28,629

 

 

 

 

 

 

 

 

 

 

 

 

 

 

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION (UNAUDITED)

AS AT 30 JUNE 2019

 

 

 

 

Notes

30 June 2019

£'000

30 June 2018

£'000

31 Dec 2018

£'000

Non-current assets

 

 

 

 

Property, plant and equipment

 

2,917

2,879

2,828

Intangible assets

 

19,614

19,486

19,938

Total non-current assets

 

22,531

22,365

22,766

Current assets

 

 

 

 

Inventory

 

2,738

2,540

2,330

Trade and other receivables

 

3,041

3,554

3,551

Corporation tax receivable

 

900

925

1,200

Cash and cash equivalent

 

10,076

12,215

7,816

Total current assets

 

16,755

19,234

14,897

Total assets

 

39,286

41,599

37,663

Non-current liabilities

 

 

 

 

Long term debt

 

(5,790)

(3,713)

-

Deferred tax

 

(755)

(797)

(791)

Total non-current liabilities

 

(6,545)

(4,510)

(791)

Current liabilities

 

 

 

 

Trade and other payables

 

(4,112)

(1,355)

(4,302)

Total current liabilities

 

(4,112)

(1,355)

(4,302)

Total liabilities

 

(10,657)

(5,865)

(5,093)

Net assets

 

28,629

35,734

32,570

Equity

 

 

 

 

Share capital

6

5,859

5,859

5,859

Share premium

6

86,398

86,398

86,398

Merger Reserve

6

10,884

10,884

10,884

Reverse acquisition reserve

6

(7,148)

(7,148)

(7,148)

Reserve for own shares

 

(831)

(831)

(831)

Share based payment reserve

 

1,147

1,398

1,129

Retained earnings deficit

7

(67,172)

(60,328)

(63,239)

Equity attributable to equity holders of parent

 

29,137

36,232

33,052

Non-controlling interests

 

(508)

(498)

(482)

Total equity

 

28,629

35,734

32,570

 

Approved by the Board and authorised for issue on 10 September 2019

 

 

 

CONDENSED CONSOLIDATED CASH FLOW STATEMENT (UNAUDITED)

FOR THE SIX MONTHS ENDED 30 JUNE 2019

 

 

 

 

 

Notes

6 months to

30 June 2019

£'000

6 months to

30 June 2018

£'000

12 months to

31 Dec 2018

£'000

Operating Activities

Operating loss

 

 

(4,220)

 

(4,736)

 

(8,689)

Adjustment for non-cash items:

 

 

 

 

Depreciation of property, plant & equipment

 

273

283

598

Amortisation of intangible assets

 

282

267

575

Share based payment

 

18

212

(57)

Research tax credit received

 

653

1,047

1,225

Finance Charges

 

(183)

(28)

-

Operating cash outflow

 

(3,177)

(2,955)

(6,348)

Increase/ decrease in inventory

 

(408)

399

542

Increase/ decrease in trade & other receivables

 

468

(603)

(1,188)

Increase/ decrease in trade & other payables

 

(482)

(1,007)

156

Net cash outflow from operations

 

(3,599)

(4,166)

(6,838)

Investing activities

 

 

 

 

Interest received

 

11

42

72

Purchase of property, plant & equipment

 

(366)

(113)

(290)

Capitalised development expenditure

 

-

(24)

(116)

Acquisition of subsidiary

 

-

-

(1,564)

Net cash outflow from investing activities

 

(355)

(95)

(1,898)

Financing activities

 

 

 

 

Proceeds from issue of share capital

 

-

-

-

Proceeds from exercised share options

 

-

4

4

Proceeds from loan

 

6,114

-

-

Net cash inflow from financing activities

 

6,114

4

4

Increase/ (decrease) in cash and cash equivalents

 

2,160

(4,257)

(8,732)

Foreign exchange translation movement

 

100

49

125

Cash and cash equivalents at start of period

 

7,816

16,423

16,423

Cash and cash equivalents at end of period

 

10,076

12,215

7,816

 

 

 

 

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

FOR THE SIX MONTHS ENDED 30 JUNE 2019

 

 

1.   Basis of preparation

The condensed financial statements are not statutory accounts, have not been audited and, as permitted under the AIM Rules, do not comply with IAS 34 "Interim Financial Reporting".                                                                                                                                                                                           

The accounting policies adopted are in accordance with International Financial Reporting Standards and are consistent with those expected to be applied in the preparation of the audited financial statements for the year ending 31 December 2019, including the adoption of the following new standard with effect from 1st January 2019:

 

·      IFRS 16 Leases

                                                                                                           

The comparative figures for the year ended 31 December 2018 are from the statutory accounts. Those accounts have been reported on by the Company's Auditor and delivered to the Registrar of Companies. The report of the Auditor was unqualified, did not include reference to any matters by way of emphasis and did not contain a statement under section 498 of the Companies Act 2006.                                                                                                         

This is the first set of results since the adoption of IFRS 16 which has caused no material impact to the Group's financial statements as the Group has been able to benefit from the exemption for leases with less than 12 months left to run.                                                                                                                                                                                                           

2.   Segmental reporting

 

The following table provides disclosure of the Group's revenue by geographical market based on location of the customer:

 

 

 

Notes

6 months to

30 June 2019

£'000

6 months to

30 June 2018

£'000

12 months to

31 Dec 2018

£'000

USA

 

4,961

4,559

9,434

Rest of world

 

1,108

1,015

2,185

 

 

6,069

5,574

11,619

 

 

 

6 months to 30 June 2019

BioSurgery

Orthopaedics & Dental

Cardiac

Other

Central

Total

£'000

£'000

£'000

£'000

£'000

£'000

Revenue

1,963

3,049

-

1,057

-

6,069

Cost of sales

(1,095)

(1,430)

-

(700)

-

(3,225)

Gross Profit

868

1,619

-

357

-

2,844

Administrative costs

(2,018)

(2,319)

(193)

(289)

(2,205)

(7,024)

Exceptional costs

-

 

-

-

(40)

(40)

Operating loss

(1,150)

(700)

(193)

68

(2,245)

(4,219)

Finance income

-

-

-

-

11

11

Finance charges

-

-

-

-

(183)

(183)

Loss before taxation

(1,150)

(700)

(193)

68

(2,417)

(4,392)

Taxation

-

-

-

-

311

311

Loss for the year

(1,150)

(700)

(193)

68

(2,106)

(4,081)

 

 

 

 

6 months to 30 June 2018

BioSurgery

Orthopaedics & Dental

Cardiac

Other

Central

Total

£'000

£'000

£'000

£'000

£'000

£'000

Revenue

1,478

3,205

-

891

-

5,574

Cost of sales

(732)

(1,115)

-

(604)

-

(2,451)

Gross Profit

746

2,090

-

287

-

3,123

Administrative costs

(2,042)

(2,835)

(224)

(272)

(1,986)

(7,359)

Exceptional costs

-

-

-

-

(500)

(500)

Operating loss

(1,296)

(745)

(224)

15

(2,486)

(4,736)

Finance income

-

-

-

-

42

42

Finance charges

-

-

-

-

(146)

(146)

Loss before taxation

(1,296)

(745)

(224)

15

(2,590)

(4,840)

Taxation

(6)

259

52

-

-

305

Loss for the year

(1,302)

(486)

(172)

15

(2,590)

(4,535)

 

 

 

 

12 months to 31 December 2018

BioSurgery

Orthopaedics & Dental

Cardiac

Other

Central

Total

£'000

£'000

£'000

£'000

£'000

£'000

Revenue

3,381

6,396

-

1,842

-

11,619

Cost of sales

(1,769)

(2,676)

-

(1,257)

-

(5,702)

Gross Profit

1,612

3,720

-

585

-

5,917

Administrative costs

(4,169)

(4,992)

(428)

(551)

(4,043)

(14,183)

Exceptional costs

-

-

-

-

(423)

(423)

Operating loss

(2,557)

(1,272)

(428)

34

(4,466)

(8,689)

Finance income

-

-

-

-

(190)

(190)

Finance charges

-

-

-

-

-

-

Loss before taxation

(2,557)

(1,272)

(428)

34

(4,656)

(8,879)

Taxation

73

543

102

-

(98)

620

Loss for the year

(2,484)

(729)

(326)

34

(4,754)

(8,259)

 

 

3.   Taxation

 

 

 

 

 

6 months to

30 June 2019

£'000

6 months to

30 June 2018

£'000

12 months to

31 Dec 2018

£'000

Current Tax:

 

 

 

 

UK corporation tax credit on research and development costs in the period

 

(353)

(352)

(790)

US corporation tax

 

42

47

72

 

 

(311)

(305)

(718)

Deferred tax:

 

 

 

 

Origination and reversal of temporary timing differences

 

 

-

 

-

 

98

Tax credit on loss on ordinary activities

 

(311)

(305)

(620)

 

 

 

 

 

The Group has accumulated losses available to carry forward against future trading profits. 

 

4.   Loss per share (basic and diluted)

 

Basic loss per share is calculated by dividing the loss attributable to equity holders of the parent by the weighted average number of ordinary shares in issue during the period excluding own shares held jointly by the Tissue Regenix Employee Share Trust and certain employees.  Diluted loss per share is calculated by adjusting the weighted average number of ordinary shares in issue during the period to assume conversion of all dilutive potential ordinary shares.

 

 

 

 

 

 

 

 

 

 

 

6 months to

30 June 2019

£'000

6 months to

30 June 2018

£'000

12 months to

31 Dec 2018

£'000

Total loss attributable to the equity holders of the parent

 

 

(4,055)

 

(4,446)

 

(8,186)

 

 

 

 

 

 

 

 

 

 

 

 

No.

No.

No.

Weighted average number of ordinary shares in issue during the period

 

 

1,171,534,448

 

1,171,534,448

 

1,171,633,442

Loss per share

 

 

 

 

Basic and diluted on loss for the period

 

(0.35)p

(0.38)p

(0.70)p

 

The Company has issued employees options over 23,786,780 ordinary shares and there are 16,940,386 jointly owned shares which are potentially dilutive.  There is, however, no dilutive effect of these issued options as there is a loss for each of the periods concerned.

 

5.   Interim financial report

 

A copy of this interim report is available on the Company's website at www.tissueregenix.com in accordance with AIM Rule 20.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
IR BUGDCSSGBGCC

Quick facts: Tissue Regenix Group PLC

Price: 1.125

Market: AIM
Market Cap: £13.18 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tissue Regenix "advancing on many fronts" says CEO after SurgiPure FDA clearance

Antony Odell, chief executive at Tissue Regenix (LON:TRX), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue. The group, which already has experience of commercialising products in the US, is planning a commercial...

on 03/09/2016

RNS

Holding(s) in Company

10 hours, 57 minutes ago

Holding(s) in Company

11 hours, 14 minutes ago

Second Price Monitoring Extn

2 days, 12 hours ago

Price Monitoring Extension

2 days, 12 hours ago

Holding(s) in Company

3 weeks, 6 days ago

Trading Update

3 weeks, 6 days ago

Holding(s) in Company

4 weeks, 1 day ago